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Glucose-Induced Phosphatidylinositol 3-Kinase and
Mitogen-Activated Protein Kinase–Dependent
Upregulation of the Platelet-Derived Growth Factor-
Receptor Potentiates Vascular Smooth Muscle
Cell Chemotaxis
Malcolm Campbell,1 William E. Allen,1 Jonathan A. Silversides,1 and Elisabeth R. Trimble1,2
The aim of this study was to investigate the effects of
elevated D-glucose concentrations on vascular smooth
muscle cell (VSMC) expression of the platelet-derived
growth factor (PDGF) receptor and VSMC migra-
tory behavior. Immunoprecipitation, immunofluores-
cent staining, and RT-PCR of human VSMCs showed that
elevated D-glucose induced an increase in the PDGF
receptor that was inhibited by phosphatidylinositol
3-kinase (PI3K) and mitogen-activated protein kinase
(MAPK) pathway inhibitors. Exposure to 25 mmol/l
D-glucose (HG) induced increased phosphorylation of
protein kinase B (PKB) and extracellular-regulated
kinase (ERK). All HG chemotaxis assays (with either 10
days’ preincubation in HG or no preincubation) in a FCS
or PDGF-BB gradient showed positive chemotaxis,
whereas those in 5 mmol/l D-glucose did not. Assays
were also run with concentrations ranging from 5 to 25
mmol/l D-glucose. Chemotaxis was induced at concentra-
tions >9 mmol/l D-glucose. An anti-PDGF receptor
antibody inhibited glucose-potentiated VSMC chemo-
taxis, as did the inhibitors for the PI3K and MAPK
pathways. This study has shown that small increases in
D-glucose concentration, for a short period, increase
VSMC expression of the PDGF receptor and VSMC
sensitivity to chemotactic factors in serum, leading to
altered migratory behavior in vitro. It is probable that
similar processes occur in vivo with glucose-enhanced
chemotaxis of VSMCs, operating through PDGF recep-
tor–operated pathways, contributing to the accelerated
formation of atheroma in diabetes. Diabetes 52:
519–526, 2003
Vascular disease is responsible for much of theexcess morbidity and mortality that affect pa-tients with diabetes. The atherosclerotic plaquecontains components derived from both the en-
dothelial and muscle layers in addition to invading macro-
phages (1,2), as is the case for all causes of atheroma
formation. However, clinically significant atherosclerosis
occurs at an earlier age and is often more severe in
patients who suffer from diabetes than in nondiabetic
subjects (1).
Platelet-derived growth factor (PDGF), secreted by vas-
cular cells, plays a central role in the development of
atherosclerotic proliferation of vascular smooth muscle
cells (VSMCs) (2). PDGF also stimulates chemotaxis (3).
The effects of PDGF are mediated through binding to
specific high-affinity surface receptors (4). Since PDGF
receptors are found on VSMCs (5) and macrophages (6),
this suggests that PDGF could influence atherosclerosis by
regulating the functions of both macrophages and VSMCs.
Macrophages are present at all stages of development of
the atherosclerotic plaque. Macrophages adhere to endo-
thelial cells, move between these cells, and accumulate in
the subendothelial space (7). Activated macrophages not
only act as scavenger cells but also secrete several growth
factors. Secretions of growth factors such as PDGF (8) and
colony-stimulating factor (CSF)-1 (9) are increased when
macrophages are activated. Glucose causes an upregula-
tion of the CSF-1 receptor (c-fms) on macrophages (10),
thereby allowing enhanced autocrine activation of the
macrophage by CSF-1.
A high glucose environment causes the development of
oxidative stress within VSMCs (11,12), and both this
and/or the presence of increased amounts of chemotactic
substances cause VSMCs to change their phenotype and
migrate into the subendothelial space. VSMCs in the
subendothelial space display a “secretory” phenotype ex-
pressing genes for a number of growth factors and their
receptors such as c-fms (2). A range of factors, such as
urokinase type plasminogen activator (13), throm-
bospondin-1 (14), bone morphogenetic protein-2 (BMP-2)
(15), tumor necrosis factor- (16), vascular endothelial
growth factor (17), and IGF-1 (18), are believed to be
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chemotactic for VSMCs. At present, PDGF is the best-
characterized chemotactic agent for VSMCs (19).
The aims of this study were to determine whether high
glucose levels per se induce alterations in the expression
of the PDGF receptor in primary human aortic VSMCs, to
determine the signaling pathways involved, and to deter-
mine whether the chemotactic properties of VSMCs are
altered by exposure to high glucose. High glucose concen-
trations cause VSMCs to divide. In this study, the move-
ment of cells has been investigated using a Dunn chamber,
which allows dividing and nondividing cells to be identi-
fied and treated separately. This assay is also more sensi-
tive than the more commonly used transwell assay (20,21).
Additionally, it allows accurate calculation of the speed of
cell movement, which cannot be assessed in the transwell
assay.
RESEARCH DESIGN AND METHODS
Chemicals and antibodies. D-Glucose and L-glucose were purchased from
BDH (Poole, UK). PDGF-BB was purchased from Insight Biotechnology
(Wembly, UK). Wortmannin and LY294002 were purchased from Sigma
(Poole, UK). PD-98059 was from Calbiochem (La Jolla, CA). Trolox and
-lopoic acid were from Sigma.
The following antibodies were used: anti-PDGF receptor and anti-PDGF
receptor antibodies (R&D Systems, Minneapolis, MN), rabbit polyclonal
antibody to total extracellular-regulated kinase (ERK) (Santa Cruz), mouse
polyclonal antibody to phosphorylated ERK (Santa Cruz), rabbit polyclonal
antibody to Akt/protein kinase B (PKB) phosphorylated on serine 473 (Cell
Signaling Technology), rabbit polyclonal antibody against Akt/PKB (Cell
Signaling Technology), and horseradish peroxidase (HRP)-conjugated donkey
anti-mouse IgG and HRP-conjugated donkey anti-rabbit IgG (Dako, Ely, UK).
Isolation of VSMCs. Porcine aorta was obtained from the local abattoir.
VSMCs were isolated and grown as previously described (11,12). Human
VSMCs were obtained from the thoracic aorta of transplant donors (written
consent was obtained from the relevant family member, and the study was
approved by the Ethical Committee of Queen’s University, Belfast). The
VSMCs were isolated as previously described (11,12), except that the growth
medium was RPMI-1640 (GibcoBRL, Life Technologies, Paisley, UK) instead
of Dulbecco’s modified Eagle’s medium (GibcoBRL). Cells were confirmed as
VSMCs by positive immunofluorescence staining with a monoclonal antibody
against smooth muscle -actin. All VSMC experiments were carried out using
cells of passage 4–7.
Chemotaxis assays. Chemotaxis was assessed by direct observation and
recording of cell behavior in stable concentration gradients of FCS using the
Dunn chemotaxis chamber (Weber Scientific International, Teddington, UK).
This apparatus permits the direction of migration of individual cells to be
measured in relation to the direction of the gradient, as well as the time course
of the response to be followed (20–22). The chamber was set up, filmed, and
the data analyzed as previously described (20–22). In FCS gradient experi-
ments, FCS-free medium was placed in the inner well and 10% FCS medium in
the outer well. For PDGF-BB gradient experiments, cells were serum starved
for 4 h before the Dunn chamber was assembled. In these experiments, the
medium in the outer well was replaced with serum-free medium containing 10
ng/ml PDGF-BB (Insight Biotechnology). Experiments were run for 18 h with
a time-lapse interval of 10 min. To test for chemotaxis, the Rayleigh test for
unimodal clustering of directions was applied to the data and a P value of
0.01 was chosen as the criterion for rejecting the null hypothesis of random
directionality (23). Where there was significant unimodal clustering, the mean
direction and its 95% CI were calculated. The Student’s t test was used to
compare migration speeds between experiments.
This assay was used to test a range of glucose conditions and the following
pharmacological agents: wortmannin (10 nmol/l) and LY294002 (10 mol/l)
(phosphatidylinositol 3-kinase [PI3K] inhibitors), PD-98059 (10 mol/l) (a
mitogen-activated protein kinase [MAPK] inhibitor), and blocking antibodies
against the PDGF and - receptors.
Immunofluorescence. For immunofluorescence studies, cells were fixed in
4% formaldehyde in PBS for 20 min at room temperature and then permeabil-
ized with 0.5% Triton X-100 in PBS containing 1% BSA for 10 min. Actin
filaments were stained by incubation with 0.1 mg/ml tetramethyl rhodamine
isothiocyanate (TRITC)-labeled phalloidin (Sigma Chemical) for 60 min. For
localization of the PDGF receptor, cells were incubated for 60 min at room
temperature with a 1:200 dilution of goat anti-PDGF receptor (R&D Systems)
in a PBS/1% BSA blocking buffer before incubation for 60 min with 1:100
fluorescein isothiocyanate-conjugated mouse anti-goat IgG (Caltag) in block-
ing buffer. Staining for the PDGF receptor was carried out as for the PDGF
receptor, with the substitution of the PDGF receptor antibody.
Immunoprecipitation. Adherent cells were washed with ice-cold PBS,
incubated in RIPA buffer on ice for 20 min before being scraped, and left on
ice for 60 min. Cell lysate was centrifuged at 10,000 rpm for 10 min. Mouse
IgG1 (0.25 g) (Dako) and 20 l protein A-G Plus Agarose (Santa Cruz) were
added to lysate containing 200 g protein for each condition and incubated at
4°C for 30 min. The supernatant was removed to fresh tubes after centrifuga-
tion at 2,500 rpm for 5 min. Mouse anti-PDGF receptor (5 l), rabbit anti-ERK
(5 l) (Santa Cruz), mouse anti-pERK (5 l) (Santa Cruz), rabbit anti-pPKB
(Cell Signaling Technology), or rabbit anti-PKB (Cell Signaling Technology)
was added to the supernatant and incubated at 4°C for 1 h. Protein A-G Plus
Agarose (20 l) was added to the mixture and incubated overnight at 4°C. The
mixture was then pelleted by centrifugation at 2,500 rpm for 5 min. The pellet
was washed four times with ice-cold RIPA buffer. After the final wash, the
pellet was resuspended in 40 l of Laemli buffer. For Western blotting,
proteins were resolved in 4–20% Tris HCl gels and transferred to nitrocellu-
lose membrane at 200 mA for 2 h (Amersham Pharmacia Biotech, Bucking-
hamshire, UK). Membranes were blocked with PBS/5% fat-free dried milk/0.1%
Tween 20. For detection, rabbit anti-ERK (Santa Cruz), mouse anti-pERK
(Santa Cruz), rabbit anti-pPKB (Cell Signaling Technology), rabbit anti-PKB
(Cell Signaling Technology), or mouse anti-PDGF receptor (R&D Systems)
were used at a dilution of 1:500. Detection was with HRP-conjugated donkey
anti-rabbit IgG (Dako) or HRP-conjugated donkey anti-mouse IgG (Dako) at
1:1,000 and enhanced chemiluminescence (Supersignal Ultra; Pierce, Rock-
ford, IL). UK Analysis of results was carried out by densitometry (GS-670
Imaging densitometer; Bio-Rad Laboratories).
RT-PCR. Total RNA was extracted using a RNeasy midi kit (Qiagen) before
one-step RT-PCR using a Reverse-It One-Step kit (ABgene, Epsom, UK).
Briefly, 1 g RNA was added to ReddyMix RT-PCR master mix containing 0.2
mol/l sense/antisense primers (PDGF forward primer corresponds to
nucleotides 2,805–2,824 and PDGF reverse primer to nucleotides 3,317–3,300
of the PDGF cDNA) (24), 1.25 units Thermoprime Plus DNA polymerase, 0.2
mm dNTP mix, 1.5 mm MgCl2, and 2.5 units Reverse-It Blend. The reactions
were subjected to the following cycling conditions: first-strand synthesis
(47°C for 30 min), RTase inactivation and initial denaturation (94°C for 2 min
followed by 30 cycles of denaturation 94°C for 20 s), annealing (50°C for 30 s),
and extension (72°C for 1 min); final extension was performed at 72°C for 5
min. Target mRNA was coamplified with the internal control (GAPDH), which
acted as a control for sample-to-sample variation in RT and PCR and
monitored the extent of degradation and recovery of RNA. PCR were
separated using 1.2% Agarose gel before visualization and quantification using
Gene Tools analysis software (Snygene, Poole, Dorset, UK).
RESULTS
Glucose induces increased growth factor receptor
expression in VSMCs. To determine the effect of expo-
sure to elevated D-glucose, immunofluorescent staining,
immunoprecipitation, and RT-PCR were carried out for
the PDGF receptor.
Confocal laser microscopy demonstrated that human
VSMCs express the PDGF receptor (Fig. 1A and B).
Comparison of the cells cultured in 5 mmol/l (Fig. 1A) and
25 mmol/l D-glucose (Fig. 1B) suggested that the PDGF
receptors were increased in 25 mmol/l D-glucose; quanti-
tative image analysis revealed a 110% increase compared
with 5 mmol/l D-glucose in staining for the PDGF recep-
tor in 25 mmol/l D-glucose. Immunofluorescent staining
also demonstrated that human VSMCs express the PDGF
receptor; however, no change in expression was detected
between 5 and 25 mmol/l D-glucose (data not shown).
Western blotting of human and porcine VSMC-immuno-
precipitated lysates was carried out to gain a more quan-
titative comparison of the expression of the PDGF
receptor between 5 and 25 mmol/l glucose. Densitometry
showed that VSMCs exposed to 25 mmol/l D-glucose for 1
day had a 60% increase in the PDGF receptor compared
with 5 mmol/l (Fig. 1C), whereas VSMCs exposed to 25
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mmol/l D-glucose for 10 days showed a 214% increase in
the PDGF receptor compared with 5 mmol/l D-glucose.
To determine how high the glucose concentration
needed to be to cause an increase in PDGF receptor
expression, VSMCs exposed to a range of glucose concen-
trations from 5 to 25 mmol/l for 24 h were stained.
Quantitative image analysis showed that with increasing
glucose concentration up to 10 mmol/l, PDGF receptor
expression increased before leveling off at concentrations
between 10 and 25 mmol/l (Fig. 1D).
RT-PCR showed that 24 h exposure to 25 mmol/l glucose
induced a significant increase in PDGF receptor mRNA
(Fig. 1E).
Glucose induces increased PDGF receptor expres-
sion via PI3K and MAPK pathways. Pharmacological
agents were used to determine which major second mes-
senger systems regulate glucose-induced increases in
PDGF receptor expression. VSMCs were placed in 25
mmol/l glucose in the presence of standard concentrations
of wortmannin (10 nmol/l), LY294002 (10 mol/l) (PI3K
inhibitors), or PD-98059 (10 mol/l) (MAPK inhibitor) for
24 h. Immunoprecipitation and RT-PCR were carried out
for the PDGF receptor. Treatment with wortmannin or
LY294002 led to significant reduction of the PDGF recep-
tor protein, as did treatment with PD-98059 (Fig. 2A).
These agents were dissolved in DMSO, necessitating a
DMSO control. To determine whether this inhibition effect
was specific to the effects of high glucose, LY294002 and
PD-98059 were also tested in 5-mmol/l glucose conditions.
In 5 mmol/l glucose, both LY294002 and PD-98059 caused
a slight reduction in expression of the receptor. RT-PCR
showed that both LY294002 and PD-98059 cause signifi-
cant inhibition of the PDGF receptor mRNA levels com-
pared with the 25 mmol/l glucose/DMSO control (Fig. 2B).
These results indicate that the glucose-induced upregu-
lation of the PDGF receptor is PI3K and MAPK depen-
dent and that there is a low level of PI3K and MAPK
pathway activity in 5 mmol/l D-glucose.
Glucose leads to increased phosphorylation of PKB
and ERK. The effects of glucose on the PI3K pathway was
assessed by investigation of protein kinase B (PKB or Akt)
a downstream target for PI3K. Immunoprecipitation was
carried out for total PKB and phosphorylated PKB. Densi-
tometry revealed that levels of total PKB were not altered
by exposure to 25 mmol/l glucose (Fig. 3A), but that after
24 h exposure to 25 mmol/l glucose, there was an increase
FIG. 1. Expression of PDGF receptors on
VSMCs. Human VSMCs were stained for the
PDGF receptor in conditions of 5 (A) or 25
mmol/l glucose (B) for 24 h. Cells were
stained for the receptors (green) and f-actin
(red). This receptor was expressed, and
present in greater quantity, in cells exposed
to 25 mmol/l glucose (quantitative image
analysis indicates a 110% increase). Scale
bar represents 10 m. Immunoprecipitation
and Western blotting of VSMCs revealed that
after a 1-day exposure to 25 mmol/l D-glucose
(HG1), VSMCs show a 60% increase, and that
after a 10-day exposure to 25 mmol/l glucose
(HG10), show a 214% increase in PDGF
receptor when compared with 5 mmol/l glu-
cose (NG) (n  6) (C). Quantitative image
analysis of VSMCs exposed to concentra-
tions of glucose ranging from 5 to 25 mmol/l
and stained for PDGF receptor showed that
expression of this receptor increases with
increasing glucose concentration up to 10
mmol/l glucose. Above this concentration,
receptor expression plateaus (n  3) (D).
RT-PCR showed that 24 h exposure to 25
mmol/l glucose significantly increased
PDGF receptor mRNA (n  14). *P < 0.05
vs. NG; #P < 0.05 vs. HG1.
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of phosphorylated PKB compared with 5 mmol/l glucose
(Fig. 3B), and that after 10 days’ exposure to 25 mmol/l
glucose, the levels of phosphorylated PKB were further
increased (Fig. 3B). Exposure to 5 mmol/l D-glucose plus
20 mmol/l L-glucose had no effect on either total PKB
expression or the amount of phosphorylated PKB.
To further investigate the role of the MAPK pathway,
immunoprecipitation was carried out for total ERK 1/2
(Fig. 3C) and phosphorylated ERK 1/2 (Fig. 3D). No
significant increase in the expression of ERK 1/2 was
detected (Fig. 3C); however, measurement of phosphory-
lated ERK showed a significant increase in ERK 1/2
phosphorylation after 24-h exposure to 25 mmol/l glucose,
which increased further after 10 days’ exposure (Fig. 3D).
Exposure to 5 mmol/l D-glucose plus 20 mmol/l L-glucose
had no effect on either total ERK 1/2 expression or the
amount of phosphorylated ERK 1/2.
To address the possibility that the changes in PKB and
ERK activity was caused by increased oxidative stress,
PKB and ERK were measured in cells exposed to the
antioxidants -lipoic acid (50 mol/l) and Trolox (200
mol/l) in 25 mmol/l D-glucose. No effect was noted (data
not shown).
Glucose sensitizes VSMCs to PDGF and serum fac-
tors. To test the effects of increased glucose concentra-
tions on human VSMC migration, cells were exposed to a
gradient of FCS in either 5 or 25 mmol/l D-glucose using the
Dunn chemotaxis chamber. The 25 mmol/l D-glucose–
treated cells had been preincubated in 25 mmol/l D-glucose
for 10 days before the experiment. In 5 mmol/l D-glucose,
the human VSMCs moved randomly (Fig. 4A). By contrast,
in 25 mmol/l D-glucose, the cells showed chemotaxis
toward the source of the FCS (Fig. 4B). This experiment
was repeated using porcine VSMCs; again in 5 mmol/l
D-glucose, the cells moved randomly in the FCS gradient
but chemotaxed in 25 mmol/l D-glucose (data not shown).
To test whether a 10-day exposure to 25 mmol/l
D-glucose was required to induce this alteration in behav-
ior, human VSMCs cultured in 5 mmol/l D-glucose were
exposed to 25 mmol/l D-glucose only when placed in the
FIG. 2. Effects of PI3K and MAPK inhibitors on PDGF receptor
expression. Immunoprecipitation and Western blotting of VSMCs re-
vealed that after 24 h exposure to 25 mmol/l D-glucose (HG) and
treatment with the PI3K inhibitors wortmannin (10 nmol/l) (Wtm) or
LY294002 (10 mol/l) (LY), or the MAPK inhibitor PD-98059 (10
mol/l) (PD), the expression of the PDGF receptor was significantly
reduced compared with the HG DMSO control (n  5) (A). RT-PCR of
VSMCs also revealed that after 24 h exposure to HG and treatment
with LY294002 or PD-98059, the mRNA levels for the PDGF receptor
were significantly reduced compared with the HG DMSO control (n 
4) (B). *P < 0.05 vs. 5 mmol/l glucose; #P < 0.05 vs. HG/DMSO.
FIG. 3. Effects of high glucose concentration on PKB and ERK phos-
phorylation. Immunoprecipitation and densitometry showed that ex-
posure to 25 mmol/l D-glucose had no significant effect on the
expression of total PKB after either 1 or 10 days. Ten days’ exposure to
5 mmol/l D-glucose and 20 mmol/l L-glucose (osmotic and glycation
control) had no significant effect on total PKB expression (A). High
D-glucose exposure for 1 day increased the levels of PKB phosphoryla-
tion, which increased further with 10 days’ exposure; however, 10 days’
exposure to 5 mmol/l D-glucose and 20 mmol/l L-glucose had no signif-
icant effect on PKB phosphorylation (B). Immunoprecipitation and
densitometry showed that exposure to 25 mmol/l D-glucose or 5 mmol/l
D-glucose and 20 mmol/l L-glucose had no significant effect on the
expression of total ERK 1/2 after either 1 or 10 days (10 days only for
L-glucose) (C). Exposure to 25 mmol/l glucose for both 1 and 10 days
significantly increased the level of ERK 1/2 phosphorylation, but 10
days’ exposure to 5 mmol/l D-glucose plus 20 mmol/l L-glucose did not
(D) (n  8). *P < 0.05 vs. 5 mmol/l glucose; # P < 0.05 vs. 25 mmol/l
glucose for 1 day.
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chemotaxis chamber. As with the 10-day preincubation
experiments, the cells showed chemotaxis (Fig. 4C).
Intermediate concentrations of D-glucose were tested. It
was shown that in 15, 10, and 9 mmol/l D-glucose (without
preincubation), there was chemotaxis (Fig. 4D, E, and F,
respectively). However, in 8 mmol/l D-glucose, there was
no chemotaxis (Fig. 4G). Because PDGF is known to be a
chemotactic agent for VSMCs and because high glucose
upregulates the PDGF receptor (Fig. 1), human VSMCs
were preincubated for 5 h with either an antibody against
the PDGF receptor (1 g/ml) or the PDGF receptor (1
mg/ml) in 25 mmol/l D-glucose before being exposed to a
gradient of FCS, in order to determine whether PDGF
plays a role in the chemotaxis to FCS in high glucose
concentrations. The PDGF receptor antibody blocked
chemotaxis in the FCS gradient (Fig. 4H); however, the
PDGF receptor antibody did not inhibit chemotaxis (Fig.
4I). Incubation with a nonrelevant IgG of the same species
and class had no effect on chemotaxis (data not shown).
This indicated that PDGF within the FCS played a key role
in producing the chemotaxis shown in Fig. 4B. Control
experiments were carried out to eliminate the possibility
that the change in migratory behavior was caused by
either osmosis or glycation. To achieve this, human
VSMCs were exposed to 5 mmol/l D-glucose plus 20 mmol/l
L-glucose for 10 days and did not show chemotaxis (Fig.
4J). A second control was carried out to eliminate the
possibility that some characteristic of the Dunn chemo-
taxis chamber influenced the change in VSMC behavior. In
these experiments, human VSMCs in 25 mmol/l D-glucose
were placed in the chamber with 10% FCS in both the
source and sink well, i.e., FCS throughout the chamber; in
the absence of an FCS gradient, there was no chemotaxis
(Fig. 4K).
The effects of glucose on PDGF-induced chemotaxis
were tested. Human VSMCs were maintained in RPMI
without FCS for 4 h before being placed in a gradient of
PDGF-BB (10 ng/ml) in either 5 or 25 mmol/l D-glucose. No
chemotaxis occurred in 5 mmol/l D-glucose (Fig. 5A),
whereas it did occur in 25 mmol/l D-glucose (Fig. 5B). A
very high concentration of PDGF-BB (30 ng/ml) did induce
chemotaxis in 5 mmol/l glucose (Fig. 5C). If cells were
preincubated with the anti-PDGF receptor antibody be-
fore being placed in a gradient of PDGF-BB in 25 mmol/l
D-glucose, no chemotaxis was observed (Fig. 5D). Again,
as a control, cells were also incubated with a nonrelevant
FIG. 5. VSMC migration in a gradient of PDGF-BB. Circular histograms
show the proportion of cells migrating in each direction, with the
source of PDGF-BB at the top. The Rayleigh test showed that cells
exposed to 5 mmol/l D-glucose and 10 ng/ml PDGF-BB (A) did not show
chemotaxis, whereas those exposed to 25 mmol/l D-glucose and 10
ng/ml PDGF-BB within the Dunn chamber did show chemotaxis (B).
Human VSMCs exposed to 5 mmol/l D-glucose in a stronger gradient (30
ng/ml) of PDGF-BB showed chemotaxis (C). Human VSMCs exposed to
25 mmol/l D-glucose preincubated for 5 h with a neutralizing anti-
PDGF receptor antibody did not show chemotaxis in a gradient of
PDGF-BB (D). All assays were run for 18 h; n represents the number of
cells tracked, and P represents Rayleigh test probability. All graphs
represent the combined results of at least four independent experi-
ments.
FIG. 4. VSMC migration in a gradient of FCS. Circular histograms show
the proportion of human VSMCs migrating in each direction, with the
source of FCS at the top. The Rayleigh test showed that cells exposed
to 5 mmol/l glucose (A) did not show chemotaxis, while those exposed
to 25 mmol/l D-glucose for 10 days did show chemotaxis to FCS (B).
Human VSMCs exposed to 25 mmol/l D-glucose, only when placed within
the Dunn chamber without a prior 10-day incubation, also showed
chemotaxis (C), as did those exposed to 15 (D), 10 (E), and 9 (F)
mmol/l glucose. However, human VSMCs exposed to 8 mmol/l glucose
did not show chemotaxis to FCS (G). Human VSMCs exposed to 25
mmol/l D-glucose and preincubated for 5 h with a neutralizing anti-
PDGF receptor antibody did not show chemotaxis in a gradient of
FCS (H). Human VSMCs exposed to 25 mmol/l D-glucose and preincu-
bated for 5 h with a neutralizing anti-PDGF receptor antibody showed
chemotaxis in a gradient of FCS (I). Human VSMCs exposed to 5
mmol/l D-glucose and 20 mmol/l L-glucose for 10 days did not show
chemotaxis to FCS (J). Human VSMCs exposed to 25 mmol/l glucose
(no 10-day preincubation) in isotonic FCS (with 10% FCS in both the
source and sink well) move randomly (K). All experiments were run for
18 h; n represents the number of cells tracked, and P represents
Rayleigh test probability. All graphs represent the combined results of
at least four independent experiments.
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IgG of the same species and class that had no effect on
chemotaxis (data not shown).
Analysis of the speed of cell movement showed a
significant drop in cell speed, at 9 mmol/l glucose and
higher, in gradients of FCS (Fig. 6).
Glucose-potentiated chemotaxis is PI3K and MAPK
dependent. VSMCs were placed in a gradient of FCS in 25
mmol/l glucose in the presence of 10 nmol/l wortmannin or
10 mol/l LY294002 or PD-98059. The cells were exposed
to each inhibitor within the chamber, and the experiments
were carried out in a darkened room due to the light
sensitivity of these inhibitors. It was found that the cells
treated with the inhibitors wortmannin (Fig. 7A),
LY294002 (Fig. 7B), and PD-98059 (Fig. 7C) did not show
chemotaxis in the FCS gradient. As these agents are
soluble in DMSO, a control experiment was run with 1
l/ml DMSO present in 25 mmol/l glucose, and the cells in
this experiment showed positive chemotaxis (Fig. 7D).
Treatment with each of these inhibitors significantly re-
duced the speed of the cells compared with untreated cells
in 25 mmol/l glucose (data not shown). These results
indicate that the D-glucose–potentiated chemotaxis in the
FCS gradient was mediated via PI3K and MAPK.
Glucose induces increased f-actin and filopodia for-
mation in VSMCs. The actin cytoskeleton is a major
component of the cellular migratory apparatus (25). Por-
cine VSMCs were fixed and stained using TRITC-conju-
gated phalloidin and then visualized using a confocal
laser-scanning microscope. This clearly showed an in-
crease in the amount of f-actin within the VSMCs exposed
to 25 mmol/l D-glucose compared with 5 mmol/l D-glucose
(Fig. 8A and B).
Staining of sparsely plated porcine VSMCs allowed the
peripheral actin structures, lamellipodia and filopodia, to
be observed. Lamellipodia are broad sheet-like structures
(Fig. 8C, arrow), while filopodia (also known as micro-
spikes) are fine spike-like actin structures (25). The num-
ber of filopodia (Fig. 8D, arrows) was increased in 25
mmol/l glucose (Fig. 8D) compared with 5 mmol/l glucose
(Fig. 8C). This finding is consistent with the chemotaxis
results, as filopodia have been shown to be essential for
chemotaxis (25).
DISCUSSION
Because PDGF is suspected to play a central role in the
proliferation and migration of VSMCs in atherosclerosis
(2,3,26), the aim of this study was to investigate in detail
the effects of exposure to elevated glucose concentrations
of primary human aortic VSMCs on the expression of the
PDGF receptors and how this altered expression affects
chemotaxis of human aortic VSMCs. The study also aimed
to determine whether PI3K- and MAPK-mediated path-
ways play a role in glucose-induced altered expression of
the PDGF receptors.
Results obtained by immunofluorescent staining and
immunoprecipitation showed that in high glucose, the
expression of the PDGF receptor is increased. RT-PCR
showed an increase in PDGF receptor mRNA, indicating
that glucose alters transcription of the gene.
Treatment with inhibitors to PI3K and MAPK showed
that glucose-induced upregulation of the PDGF receptor
is dependent on both the PI3K and MAPK pathways. This
is further supported by the finding that 25 mmol/l glucose
induced an increase in phosphorylation of both PKB (PI3K
pathway) and ERK (MAPK pathway). In light of the fact
that previous studies found that glucose-induced PDGF
receptor expression was protein kinase C dependent
(6,27), these findings indicate that the mechanisms by
which high glucose alters PDGF receptor expression are
complex.
Results obtained in this study demonstrated that raised
concentrations of glucose were able to increase the sen-
sitivity of VSMCs to serum factors and PDGF-BB, inducing
chemotaxis in a gradient of FCS. It may seem surprising
that in 5 mmol/l D-glucose, VSMCs do not show chemo-
taxis to FCS or PDGF-BB. Many cells will show chemo-
taxis in a gradient of FCS (regardless of glucose
FIG. 6. Speed of movement. Bar graph showing the mean speeds (and
standard errors) of human VSMCs exposed to various glucose concen-
trations within the Dunn chamber, in a gradient of FCS. Speed of cell
movement was significantly reduced in glucose concentrations >9
mmol/l (i.e., in all concentrations of glucose in which chemotaxis to
FCS occurs). 25*, cells exposed to 25 mmol/l D-glucose for 10 days (all
other cells were maintained in 5 mmol/l glucose before the experi-
ment). *P < 0.05 vs. 5 mmol/l glucose.
FIG. 7. Glucose-potentiated VSMC chemotaxis is PI3K and MAPK
dependent. Circular histograms show the proportion of human VSMCs
migrating in each direction, with the source of FCS at the top. The
Rayleigh test showed that cells exposed to 25 mmol/l glucose and
incubated in 10 nmol/l wortmannin (a PI3K inhibitor) failed to show
chemotaxis (A), as did those exposed to 25 mmol/l glucose and the 10
mol/l LY294002 (another PI3K inhibitor) (B). The Rayleigh test also
showed that cells treated with 10 mol/l PD-98059, a MAPK inhibitor
(C), and exposed to 25 mmol/l D-glucose do not show chemotaxis. A
control experiment was run with cells exposed to 25 mmol/l glucose
and DMSO (as wortmannin, LY294002 and PD-98059 are soluble in
DMSO), which showed chemotaxis (D). All experiments were run for
18 h; n represents the number of cells tracked, and P represents
Rayleigh test probability. Graphs show the combined results of three to
four independent experiments.
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concentration) if cultured in the absence of FCS for an
extended period of time (which upregulates receptor
expression); however, without this serum starvation, most
cells will not respond to a gradient of FCS. Increasing the
concentration of PDGF-BB to 30 ng/ml induced chemo-
taxis in 5 mmol/l glucose.
The change in chemotactic behavior occurred after
short periods of exposure to relatively modest increases in
the concentration of glucose. This was an interesting
finding in light of the high-glucose–induced increase in
PDGF receptors. It is possible that this upregulation of
receptors could explain the greater sensitivity of VSMCs to
FCS and PDGF-BB in high glucose than in normal glucose;
this conclusion was supported by the observation that
treatment with an antibody against the PDGF receptor
prevented human VSMC chemotaxing in either the FCS or
PDGF-BB gradients. Use of both PI3K and MAPK pathway
inhibitors blocked glucose-potentiated VSMC chemotaxis,
again showing the importance of these pathways in glu-
cose-modified VSMC biology.
Morphological examination of the actin cytoskeleton
showed both an increase in total f-actin and an increase in
the number of filopodia in VSMCs exposed to raised
concentrations of glucose. This is an interesting finding
since it has been previously shown that filopodia play a
crucial role in macrophage chemotaxis (25).
Glucose has been shown to directly stimulate cell
migration in a human umbilical vein endothelial cell
(HUVEC)-derived cell line (24). By contrast, high glucose
concentrations have been shown to inhibit neural crest
cell migration in rat embryos (28). It is also possible that
other high-glucose–induced processes, such as polyol ac-
cumulation (29), nonenzymatic glycation of proteins (29–
32), and altered redox potential (33), mediate this change
in migratory behavior. Yasunari et al. (34), who preincu-
bated cells in high glucose for 72 h, found that the aldose
reductase inhibitor epalrestat did inhibit glucose potenti-
ated VSMC chemotaxis to PDGF, suggesting a role for the
polyol pathway. However, it is well established that in high
glucose, it requires 2–3 days for the subsequent increase in
diacylglycerol levels to rise in VSMCs (35–37); therefore,
since the chemotatic behavior shown in the present study
occurred without prior incubation in high glucose, it is
unlikely that it is mediated by this mechanism. The recep-
tor for advanced glycation end products has been shown
to mediate rabbit smooth muscle cell chemotaxis (38). In
the present study, chemotaxis occurred without prior
incubation in glucose but did not occur when cells were
incubated for 10 days with L-glucose, which, although not
metabolized, can cause glycation. This suggests that ad-
vanced glycation end product–related phenomena were
not responsible for the chemotactic behavior of VSMCs in
high glucose seen in the present study.
It is perhaps surprising that in the present study, the
speed of cell movement was significantly lower in concen-
trations of glucose that potentiate chemotaxis to FCS, i.e.,
9 mmol/l D-glucose and higher. In macrophages, inhibition
of Cdc42, which leads to loss of chemotaxis to CSF-1, also
causes an increase in the speed of cell movement (25),
suggesting that movement by chemotaxis is slower than
random movement.
In conclusion, the results presented above show that
exposure to even modest and short-lived increases in
glucose concentration potentiate VSMC chemotaxis to
serum factors by inducing an upregulation of PDGF recep-
tors and possibly other growth factor receptors by PI3K
FIG. 8. The VSMC actin cytoskeleton. Porcine VSMCs
were exposed to either 5 or 25 mmol/l glucose for 24 h,
fixed, and stained with TRITC-conjugated phalloidin to
allow visualization of the actin cytoskeleton. These
stained cells were imaged using a confocal laser-scan-
ning microscope. In the cells exposed to 25 mmol/l
glucose (B), the TRITC staining was markedly more
intense than in cells exposed to 5 mmol/l glucose (A);
because the staining protocol and all settings on the
microscope were identical, this indicates an increase in
the amount of f-actin present. Examination of the
peripheral actin cytoskeleton revealed that in 25
mmol/l glucose (D), more filopodia (arrows in D) are
present than in 5 mmol/l glucose (C). No apparent
difference in lamellipodia (arrow in C) number or
distribution was noticed. Scale bars represent 50 m.
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and MAPK signaling pathway–dependent processes.
Taken together with our earlier finding that exposure to
high glucose concentrations increases VSMC proliferation
(11,12), these findings provide the cellular basis for one of
the many mechanisms that contribute to atherosclerosis in
diabetes.
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